DUSC public release documents by medicine/medicine group
Page last updated: 10 October 2025
- Abiraterone and enzalutamide for metastatic prostate cancer, June 2016
- Adrenaline autoinjectors utilisation analysis, October 2020
- Aflibercept and ranibizumab for age-related macular degeneration, June 2015 1
- Alectinib for non-small cell lung cancer, October 2020
- Alemtuzumab for multiple Sclerosis, February 2020
- Alprazolam, October 2015
- 5-aminosalicylic acids for ulcerative colitis, September 2017
- Antibiotics, October 2014 and February 2015
- Antifungals for systemic use, September 2016
- Antipsychotics, 25 mg quetiapine, September 2016
- Antipsychotics in children and adolescents, February 2013 & June 2013
- Antipsychotics in the middle aged, February 2013 & June 2013
- Apremilast for severe chronic plaque psoriasis, September 2023
- Armodafinil for narcolepsy, 24 month predicted versus actual analysis, June 2019
- Atezolizumab for extensive-stage small cell lung cancer, September 2022
- Avelumab for merkel cell carcinoma, February 2022
- bDMARDs for ankylosing spondylitis, February 2016
- bDMARDs for ankylosing spondylitis, June 2016
- bDMARDs for chronic plaque psoriasis, June 2014
- bDMARDs for Crohn's disease, February 2015
- bDMARDS for psoriatic arthritis, October 2015
- bDMARDs for psoriatic arthritis, February 2016
- Bendamustine for the treatment of lymphoma: 24 month predicted versus actual analysis, February 2019
- Bictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV, October 2021
- Biologics for uncontrolled severe allergic and eosinophilic asthma, October 2019
- Botulinum toxin for chronic migraine, June 2017
- Botulinum toxin for spasticity and dystonia, May 2018
- Brentuximab vedotin for cutaneous and peripheral T-cell lymphoma, June 2024
- Cladribine for relapsing remitting multiple sclerosis, February 2022
- Denosumab for osteoporosis, October 2020
- Direct acting antiviral medicines for the treatment of chronic hepatitis C, September 2018
- Dornase and mannitol, cystic fibrosis, October 2014
- Dupilumab for asthma, February 2024
- Dupilumab for severe atopic dermatitis, September 2023
- Dutasteride and dutasteride with tamsulosin for benign prostatic hyperplasia, June 2015
- Eculizumab for atypical haemolytic uremic syndrome (aHUS), October 2020
- Eculizumab for aHUS, September 2017
- Eculizumab for aHUS: utilisation update, February 2019
- Erlotinib and gefitinib for non-small cell lung cancer, February 2017
- Everolimus and sunitinib for pNET, September 2017
- Everolimus for breast cancer, February 2017
- Everolimus for tuberous sclerosis complex, February 2017
- Evolocumab for hypercholesterolaemia, February 2023
- Evolocumab for heterozygous familial hypercholesterolaemia, June 2021
- Evolocumab for homozygous familial hypercholesterolaemia, October 2019
- Exenatide, October 2014
- Ezetimibe with simvastatin, October 2014
- Ferric carboxymaltose for iron deficiency anaemia, February 2017
- Fluticasone furoate+umeclidinium+vilanterol and single inhaler triple therapies for severe asthma, April 2025
- GnRH Agonists, Utilisation analysis, June 2019
- Golimumab for non-radiographic axial spondyloarthritis, October 2021
- Guanfacine for attention deficit hyperactivity disorder, June 2021
- Ibrutinib for chronic lymphocytic leaukaemia/ small lymphocytic lymphoma, October 2020
- Icatibant for hereditary angioedema, June 2015
- Idelalisib for refractory follicular B-cell non-Hodgkin lymphoma, October 2024
- Imatinib for gastrointestinal stromal tumour, February 2017
- Ipilimumab and dabrafenib for unresectable melanoma, October 2015
- Iron chelating agents, February 2014
- Ivacaftor for cystic fibrosis, February 2018
- Lenalidomide for newly diagnosed multiple myeloma, October 2019
- Lenalidomide for myelodysplastic syndrome, September 2017
- Medicines for the treatment of type 2 diabetes, September 2022
- Medicines used in the management of attention deficit hyperactivity disorder, September 2023
- Medicines for treatment, including durvalumab, of non-small cell lung cancer, September 2022
- Mifepristone and misoprostol for medical termination of pregnancy, September 2016
- Molnupiravir for SARS-CoV-2 infection, October 2024
- Multiple myeloma, September 2017
- Nab-paclitaxel for pancreatic cancer, September 2017
- Nintedanib and pirfenidone for idiopathic pulmonary fibrosis, February 2020
- Nivolumab and ipilimumab for mesothelioma, February 2024
- Nivolumab as adjuvant treatment of melanoma, September 2022
- Nivolumab plus Ipilimumab for first-line Stage IV clear cell variant renal cell carcinoma, October 2021
- Nivolumab for non-small cell lung cancer, June 2020
- Nivolumab for renal cell carcinoma, June 2020
- Novel oral anticoagulants for deep vein thrombosis, pulmonary embolism and recurrent venous thromboembolism, October 2014
- Novel oral anticoagulants for non-valvular atrial fibrillation, June 2016
- NPS analysis on HIV and PrEP medications using MedicineInsight and PBS data, October 2021
- Nusinersen for spinal muscular atrophy, February 2021
- Nutritional products, October 2015
- Ocrelizumab for relapsing-remitting multiple sclerosis, October 2020
- Ocular lubricants, June 2014
- Olaparib for ovarian, fallopian tube and primary peritoneal cancer, June 2023
- Omalizumab 24 month review, June 2014
- Omalizumab for chronic spontaneous urticaria, June 2020
- Omalizumab for chronic spontaneous urticaria, June 2023
- Opioid Analgesics, February 2020
- Opioids, October 2014
- Opioids, impact of regulatory reforms on utilisation, June 2023
- Ocular lubricants utilisation analysis PBS data, February 2021
- Ocular lubricants utilisation analysis MedicineInsight data, February 2021
- Palbociclib for locally advanced and metastatic breast cancer, February 2022
- Pazopanib and sunitinib for renal cell carcinoma, June 2014
- Pembrolizumab for locally advanced or metastatic urothelial carcinoma, October 2021
- Posaconazole 24 month review, May 2018
- Pregabalin 12 month review, October 2014
- Pregabalin 24 month review, October 2015
- Progesterone for preterm birth, February 2024
- Proton pump inhibitor (PPI) medicines for management of gastrointestinal acid related disorders, June 2022
- Ranibizumab and aflibercept: analysis of use for AMD, DMO and RVO, May 2018
- Rifaximin for hepatic encephalopathy, September 2016
- Romiplostim and eltrombopag for idiopathic thrombocytopenic purpura, June 2015
- Romosozumab for osteoporosis, February 2024
- Sapropterin for hyperphenylalaninaemia due to BH4 deficiency, 24 month predicted versus actual analysis, June 2019
- Semaglutide for Type 2 diabetes mellitus, June 2024
- Smoking cessation therapy, February 2016
- Somatropin for growth hormone therapy, June 2021
- Ticagrelor, February 2016
- Teduglutide for Short Bowel Syndrome, June 2022
- Testosterone, February 2020
- Testosterone, September 2016
- Testosterone, October 2012
- Tobramycin inhalation for cystic fibrosis, 24 month review, October 2014
- Tolvaptan for autosomal dominant polycystic kidney disease, October 2021
- Tyrosine kinase inhibitors for chronic myeloid leukaemia, October 2019
- Tyrosine kinase inhibitors for the treatment of chronic myeloid leukaemia, February 2014
- Venetoclax for chronic lymphocytic leukaemia or small lymphocytic lymphoma, September 2023
- Zanubrutinib for Waldenström macroglobulinaemia, April 2025
Suggested citation:
[1]Department of Health. Age Related Macular Degeneration: utilisation analysis. Canberra:
Department of Health; 2015. Available from http://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/aflibercept-ranibizumab-prd-2015-06
